Cancer Therapy : Preclinical RAF 265 Inhibits the Growth of Advanced Human Melanoma Tumors


Journal article


Yingjun Su, A. Vilgelm, M. Kelley, Oriana E. Hawkins, Yan Liu, K. Boyd, S. Kantrow, R. Splittgerber, Sarah P. Short, T. Sobolik, Snjezana Zaja-Milatovic, K. Dahlman, K. Amiri, A. Jiang, P. Lu, Y. Shyr, D. Stuart, S. Levy, J. Sosman, A. Richmond
2012

Semantic Scholar
Cite

Cite

APA   Click to copy
Su, Y., Vilgelm, A., Kelley, M., Hawkins, O. E., Liu, Y., Boyd, K., … Richmond, A. (2012). Cancer Therapy : Preclinical RAF 265 Inhibits the Growth of Advanced Human Melanoma Tumors.


Chicago/Turabian   Click to copy
Su, Yingjun, A. Vilgelm, M. Kelley, Oriana E. Hawkins, Yan Liu, K. Boyd, S. Kantrow, et al. “Cancer Therapy : Preclinical RAF 265 Inhibits the Growth of Advanced Human Melanoma Tumors” (2012).


MLA   Click to copy
Su, Yingjun, et al. Cancer Therapy : Preclinical RAF 265 Inhibits the Growth of Advanced Human Melanoma Tumors. 2012.


BibTeX   Click to copy

@article{yingjun2012a,
  title = {Cancer Therapy : Preclinical RAF 265 Inhibits the Growth of Advanced Human Melanoma Tumors},
  year = {2012},
  author = {Su, Yingjun and Vilgelm, A. and Kelley, M. and Hawkins, Oriana E. and Liu, Yan and Boyd, K. and Kantrow, S. and Splittgerber, R. and Short, Sarah P. and Sobolik, T. and Zaja-Milatovic, Snjezana and Dahlman, K. and Amiri, K. and Jiang, A. and Lu, P. and Shyr, Y. and Stuart, D. and Levy, S. and Sosman, J. and Richmond, A.}
}

Abstract

Purpose: The purpose of this preclinical study was to determine the effectiveness of RAF265, a multikinase inhibitor, for treatment of human metastatic melanoma and to characterize traits associated with


Share


Follow this website


You need to create an Owlstown account to follow this website.


Sign up

Already an Owlstown member?

Log in